1. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China.
- Author
-
Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, and Ortiz E
- Subjects
- Antibodies, Bacterial blood, Antibodies, Viral blood, Antibody Formation, China, Diphtheria-Tetanus-acellular Pertussis Vaccines administration & dosage, Diphtheria-Tetanus-acellular Pertussis Vaccines adverse effects, Haemophilus Vaccines administration & dosage, Haemophilus Vaccines adverse effects, Humans, Immunization Schedule, Infant, Poliovirus Vaccine, Inactivated administration & dosage, Poliovirus Vaccine, Inactivated adverse effects, Tetanus Toxoid administration & dosage, Tetanus Toxoid adverse effects, Vaccines, Combined administration & dosage, Vaccines, Combined adverse effects, Vaccines, Combined immunology, Diphtheria-Tetanus-acellular Pertussis Vaccines immunology, Haemophilus Vaccines immunology, Immunization, Secondary, Poliovirus Vaccine, Inactivated immunology, Tetanus Toxoid immunology
- Abstract
This study assessed the antibody persistence, and the immunogenicity and safety of a booster dose of a DTaP-IPV//PRP∼T (Pentaxim®, Sanofi Pasteur's AcXim family) combined vaccine and of standalone vaccines one year after primary vaccination in the People's Republic of China. Participants (N=719) previously primed with DTaP-IPV//PRP∼T at 2, 3, 4 months (Group A, N=255), 3, 4, 5 months (Group B, N=233), or DTaP (Wuhan Institute of Biological Products), PRP-T (Act-Hib®) and IPV (Imovax® Polio) at 3, 4, 5 months (Group C, N=231) received boosters of the same vaccines at 18-20 months of age. Seroprotection (SP) and seroconversion (SC) were determined before and 1 month after the booster. Safety was monitored from parental reports. In all groups 87.6-100% of participants had pre-booster protective anti-PRP, -diphtheria, -tetanus and -poliovirus antibody titers; post-booster, all SP rates were 100% and SC was ≥ 80.4% for anti-pertussis titers ≥ 4-fold increase. Reactogenicity was low for each group. These data support the use of the DTaP-IPV//PRP∼T vaccine in the People's Republic of China compared to separate DTaP, IPV, and PRP∼T administration in terms of both safety and immunogenicity., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF